Overview
Melanotan 1, also known as afamelanotide, is a synthetic peptide that mimics alpha-melanocyte-stimulating hormone (α-MSH). Unlike many peptides in the research space, Melanotan 1 holds FDA approval as Scenesse for a specific clinical indication: preventing phototoxicity in adults with erythropoietic protoporphyria (EPP). Beyond this approved use, it is studied off-label for skin pigmentation, photoprotection, and select dermatological conditions.
The compound works by stimulating melanocortin receptors on melanocytes to increase skin pigmentation through eumelanin production—the brown and black melanin that provides natural UV protection. A key distinction from Melanotan 2 is Melanotan 1's selective binding to the MC1R receptor, which means it produces robust skin-darkening effects while avoiding the appetite and sexual side effects associated with less selective melanocortin agonists.
This article reviews the evidence for Melanotan 1 across multiple health outcomes, with an honest assessment of what the science actually supports versus what remains theoretical.
How It Works: Mechanism of Action
Melanotan 1 functions as a potent agonist at the melanocortin-1 receptor (MC1R) on melanocytes. When activated, MC1R triggers a cAMP-mediated signaling cascade that increases tyrosinase activity—the enzyme responsible for melanin synthesis.
The compound is highly selective for MC1R, which concentrates its effects on skin pigmentation. This selectivity matters because melanocortin receptors exist throughout the body (MC3R, MC4R, and MC5R in the central nervous system and peripheral tissues). By sparing these other receptors, Melanotan 1 avoids centrally mediated effects on appetite suppression and sexual function that plague less selective melanocortin agonists.
The pigmentation process shifts melanin production toward eumelanin (brown/black pigment) over pheomelanin (red/yellow pigment). Eumelanin is photoprotective—it absorbs and dissipates UV radiation, providing intrinsic sun protection without UV exposure. This mechanism is why Melanotan 1 is clinically useful in light-sensitive dermatologic conditions.
Evidence by Health Goal
Skin & Hair Pigmentation
Evidence Tier: Tier 3 (Probable Efficacy)
This is Melanotan 1's strongest evidence base. Multiple human studies demonstrate consistent skin-darkening effects with photoprotective benefit.
In a randomized controlled trial with UV-B exposure (n=24), Melanotan 1 plus UV-B significantly enhanced tanning that persisted at least 3 weeks longer than sunlight exposure alone. Treated sites showed 47% fewer sunburn cells at irradiated sites compared to controls—a meaningful indicator of photoprotection.
In erythropoietic protoporphyria (EPP) patients receiving afamelanotide via subcutaneous implant (n=20), phototoxic burn tolerance time increased dramatically from a median of 15 minutes to 250 minutes. Quality of life scores improved from 11.11 to 79.17 on their measurement scale. These patients—normally unable to tolerate outdoor light—gained functional sun exposure.
The mechanism is well-established through basic science: MC1R activation on melanocytes reliably increases eumelanin production, which provides UV absorption and dissipation. The evidence supports use for cosmetic skin darkening and, more importantly, for photosensitivity disorders.
Anti-Inflammation
Evidence Tier: Tier 3 (Probable Efficacy)
As an α-MSH analogue, Melanotan 1 demonstrates anti-inflammatory effects in small human studies, though the evidence base remains limited.
In a pilot acne vulgaris trial (n=3, RCT), total inflammatory lesions declined in all patients by day 56 of treatment. All three patients showed improved Dermatology Life Quality Index scores post-treatment. Only one patient reported mild transient fatigue; no serious adverse effects occurred.
In a solar urticaria trial (n=5, RCT), patients receiving Melanotan 1 showed mean increases in minimum urticarial dose of 1–12 increments at day 30 and 1–3 increments at day 60. Weal area fell significantly, and mean melanin density increased measurably at days 7, 15, and 60. These results suggest both photoprotection and immune tolerance to UV-induced urticaria.
The theoretical mechanism involves melanocortin receptor signaling in immune cells, but the human evidence remains limited to small pilot studies without large-scale replication or meta-analysis.
Fat Loss & Metabolic Health
Evidence Tier: Tier 2 (Theoretical Relevance)
No direct human evidence shows Melanotan 1 causes fat loss. However, melanocortin receptors—particularly MC4R—play a central role in energy homeostasis regulation. The MC4R is a key downstream target in the brain's appetite-control circuits.
As proof-of-concept, setmelanotide (a highly selective MC4R agonist) received FDA approval for certain syndromic forms of obesity. This establishes that melanocortin agonists can affect body weight and energy balance in humans. However, setmelanotide is more selective for MC4R than Melanotan 1 is, and the evidence specifically linking Melanotan 1 to fat loss in humans is absent.
Until human trials directly assess Melanotan 1's effect on body composition or metabolic rate, claims about fat-loss efficacy remain speculative.
Liver Health
Evidence Tier: Tier 3 (Probable Efficacy in EPP)
Melanotan 1 shows protective effects on liver function, but evidence is confined to erythropoietic protoporphyria patients—a specialized disease population.
In 38 EPP patients undergoing afamelanotide treatment, protoporphyrin concentrations decreased from 21.39±11.12 to 16.83±8.24 µmol/L (p<0.0001). This reduction reflects decreased hepatic protoporphyrin accumulation, which is the pathologic hallmark of EPP and drives liver damage in the disease.
In a larger observational study of 70 EPP patients over 2,933 measurements, liver function tests improved with more frequent afamelanotide dosing, demonstrating a dose-dependent protective effect.
These findings are disease-specific. Whether Melanotan 1 provides liver protection in non-EPP populations remains unstudied.
Hormonal Balance
Evidence Tier: Tier 3 (Probable Efficacy for Quality of Life)
Melanotan 1 improves hormone-related quality-of-life outcomes in erythropoietic protoporphyria, though direct hormonal biomarker improvements are not consistently demonstrated.
In EPP patients (n=29), afamelanotide increased median pain-free sunlight exposure from 12.5 minutes to 120 minutes post-treatment (p<0.001). In a larger cohort (n=121), quality-of-life scores improved from 44% baseline to 75% during afamelanotide treatment (p<0.001). These improvements likely reflect both reduced phototoxic symptoms and increased behavioral freedom (ability to engage in normal outdoor activities).
Whether these changes involve direct effects on hormonal axes (hypothalamic-pituitary-adrenal axis, reproductive hormones, etc.) is unclear from available studies. The evidence is strongest for symptom relief and quality of life, not for hormonal biomarker modification.
Sexual Health
Evidence Tier: Tier 2 (Theoretical Relevance)
Melanocortin receptors are distributed in the brain and limbic system tissues relevant to sexual function. Bremelanotide, another melanocortin agonist, received FDA approval in 2019 for generalized hypoactive sexual desire disorder in humans—proof-of-concept that melanocortin signaling affects sexual function.
However, no primary trial data specifically demonstrate that Melanotan 1 improves sexual desire or function in humans. The selectivity of Melanotan 1 for MC1R (skin-specific) over centrally active receptors (MC3R, MC4R) means it is unlikely to replicate bremelanotide's sexual effects.
Injury Recovery
Evidence Tier: Tier 1 (No Human Evidence)
No human evidence exists for Melanotan 1 in injury recovery. While melanocortin receptors are distributed in immune-relevant tissues and α-MSH analogues show anti-inflammatory properties in vitro, no clinical trials have assessed Melanotan 1 for wound healing, muscle repair, or recovery from trauma.
Cognition
Evidence Tier: Tier 1 (No Human Evidence)
The one human trial involving afamelanotide in acute stroke patients (n=6, open-label) was a safety and feasibility study with no cognitive outcome measures. No major systemic adverse events occurred over 42 days, but this tells us nothing about cognitive efficacy.
Melanocortin receptors are present in brain tissue and have theoretical roles in stress response and cognition, but no empirical evidence demonstrates cognitive benefits from Melanotan 1.
Sleep Quality
Evidence Tier: Tier 1 (No Direct Evidence)
Melanotan 1 does not have direct sleep-enhancing evidence. In EPP patients, afamelanotide treatment resulted in 71.6% more light exposure during spring compared to untreated EPP patients (p<0.01). Bedtime shifted earlier in treated patients (23:14 ± 1:29) versus off treatment (23:45 ± 1:51; p<0.0001).
These changes indicate circadian rhythm adjustment secondary to increased daytime light exposure and activity—not a primary pharmacological effect on sleep quality or architecture.
Longevity
Evidence Tier: Tier 1 (No Evidence)
No evidence suggests Melanotan 1 improves longevity or lifespan. In EPP patients (n=139), afamelanotide did not improve bone mineral density despite concurrent cholecalciferol (vitamin D) treatment. Baseline bone mineral density was low in 82.7% of EPP patients (Z-score <0 SD), but afamelanotide treatment showed no benefit.
This finding is particularly relevant because low bone mineral density is a longevity and quality-of-life concern. The lack of benefit suggests Melanotan 1 does not address age-related bone loss.
Immune Support, Energy, Gut Health, and Heart Health
Evidence Tier: Tier 1 (No Human Evidence)
No rigorous human evidence demonstrates that Melanotan 1 improves immune function, energy levels, gut health, or cardiovascular health. While melanocortin receptors have theoretical roles in immune regulation and inflammation, the available abstracts do not present clinical efficacy data for these outcomes.